Two recent studies show the novel therapy works in people with multiple myeloma, but researchers are trying to minimize side ...

Measuring the lymphocytes—white blood cells that fight infection—in a patient's blood can be used to predict outcomes in ...

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are types of slow-growing cancers that affect a type of white blood cell called a lymphocyte. Lymphocytes are cells that help ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

What Is Marginal Zone Lymphoma? Marginal zone lymphoma (MZL) isn’t one disease. It’s a group of rare, slow-growing blood cancers. They’re known as non-Hodgkin lymphomas because they start in your ...

Doctors monitor lymphocyte and other blood cell levels to predict how your lymphoma will progress. Low lymphocyte counts may suggest that cancer has spread to your bone marrow, or it can be a side ...

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the ...

With FDA approval to treat marginal zone lymphoma (MZL), Bristol Myers Squibb’s Breyanzi has become the first CAR-T therapy ...

The U.S. Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel) for the treatment of adults with relapsed or refractory marginal zone lymphoma who have received at least ...